Despite being designated as a “Chinese military” company by the U.S. Department of Defense, the CRDMO continues its strong growth in total revenue and net profit.
The equipment will help formulation scientists assess scale-up risks using small quantities of active pharmaceutical ingredients before commercial manufacturing.
The Valladolid expansion will add capacity for steroid and non-steroid active pharmaceutical ingredients, supporting complex sterile formulations and production.
